RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer

{
  "signal_id": "26764e06-d12b-c8db-200d-71e613b9a390",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-10-25T13:45:00+00:00",
  "company": {
    "name": "Johnson & Johnson",
    "domain": "jnj.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-combination-demonstrates-77-overall-response-rate-in-first-line-treatment-of-patients-with-advanced-head-and-neck-cancer-302918746.html",
    "title": "RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer",
    "ticker": "NYSE:JNJ",
    "excerpt": "NEW BRUNSWICK, N.J. , Oct. 25, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced new results from Cohort 5 of the Phase 1b/2 OrigAMI-4 study showing deep and durable responses with first-line subcutaneous amivantamab and hyaluronidase-lpuj plus a PD-1 inhibitor and fixed-duration carboplatin chemotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). 1 These findings support the ongoing pivotal Phase 3 OrigAMI-5 study and further expand the clinical development program for subcutaneous amivantamab for patients with head and neck cancer. 2 Among patients with HNSCC other than human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC), results demonstrated a confirmed overall response rate (ORR) of 77 percent, including 14 percent achieving complete responses. 1 Tumor shrinkage was observed in all evaluable patients, and nearly two-thirds of responses remained ongoing at a median follow-up of 10.6 months. 1 These findings were presented as a rapid oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026 (Abstract #1539RO). An application for RYBREVANT FASPRO in later-line head and neck cancer is also under Priority Review with the U.S. Food and Drug Administration (FDA). Unmet need remains in first-line head and neck cancer treatment For people with recurrent or...",
    "product": "RYBREVANT FASPRO",
    "summary": "Johnson & Johnson is developing subcutaneous amivantamab and hyaluronidase-lpuj (RYBREVANT FASPRO) in ongoing Phase 1b/2 and Phase 3 clinical studies for advanced head and neck cancer.",
    "location": "New Brunswick, New Jersey, United States",
    "planning": true,
    "image_url": "https://mmx.prnewswire.com/media/MS225644/Johnson-and-Johnson-Logo-v1.jpg?id=OA3037842&p=facebook",
    "confidence": 0.95,
    "product_data": {
      "name": "RYBREVANT FASPRO",
      "full_text": "subcutaneous amivantamab and hyaluronidase-lpuj",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-10-25T13:45:00Z",
    "location_data": [
      {
        "city": "New Brunswick",
        "state": "New Jersey",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "These findings support the ongoing pivotal Phase 3 OrigAMI-5 study and further expand the clinical development program for subcutaneous amivantamab for patients with head and neck cancer."
  }
}

curl https://signals.autobound.ai/v1/signals/26764e06-d12b-c8db-200d-71e613b9a390 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"jnj.com","limit":20}'